drugset
drugset / Trial / NCT06926582

A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis

NCT06926582 ↗

Phase 2 Not yet recruiting 305 enrolled Hansoh BioMedical R&D Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.

Timeline

Start
2025-04-09
Primary completion
2026-07-09
Completion
2026-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10374 Unknown 6 mg Oral

Indications

psoriasis